Your 510(k) submissions are thorough. Your pipeline is a single consultant's inbox.

Your firm lives in the gap between what a company believes it has done and what FDA will accept as sufficient. That gap is where warning letters arrive, where 483 observations accumulate, where a PMA or 510(k) stalls for months. The buyers who need you, quality directors and regulatory VPs at device and drug companies, do not browse for compliance consultants. They find you after something breaks, or they find you never.

Your Pipeline Runs on Referrals Until It Does Not

A referral from a general counsel who watched you salvage a prior warning letter is the best introduction you can get. It is also finite. The general counsel knows three firms. The quality director at the portfolio company has already hired someone. Your name circulates in a small pool, and the pool has edges.

The companies that would benefit from your work before a crisis, the ones with a Q-Sub meeting pending or a first IND submission approaching, are not in that pool. They do not know your firm exists. Email Correspondence and Direct Mail reach them directly, by name, with the specific regulatory milestone they face.

The Buyers Are Named and Reachable

FDA compliance consulting is not sold to a department. It is sold to individuals with authority to engage and budget to spend.

The primary buyers:

• VP of Regulatory Affairs at a mid-market device company preparing a De Novo submission
• Quality Director at a generics manufacturer with recurring FDA 483 observations for data integrity
• Chief Scientific Officer at a biotech with a pre-IND meeting scheduled in ninety days
• General Counsel at a pharmaceutical company managing a consent decree negotiation
• Head of R&D at a company expanding from wellness products into regulated medical devices

These individuals receive generic agency mail. They do not receive a letter naming their specific submission pathway, their known inspection history, or the FDA guidance document published last quarter that changes their obligations. That specificity is the entry.

ROI Wire builds the list from FDA registration databases, 483 and warning letter publications, SEC filings that disclose regulatory milestones, and patent filings that signal pipeline transitions. Each name is verified to the individual's current role. The correspondence reaches the person, not the mailbox.

Email Correspondence: The Regulatory Calendar as Hook

An email to a VP of Regulatory Affairs at a company that received a 483 in the prior quarter opens with the observation number and the response deadline. It notes the specific CFR citation. It states that your firm has guided similar companies through the response and the follow-up inspection.

The email does not claim a success rate. It does not attach a brochure. It offers a single paragraph of relevant experience and a direct reply address.

For a company with a 510(k) in preparation, the email references the predicate device, the FDA guidance document issued in the last eighteen months, and the common deficiency letter your firm has seen in similar submissions. It proposes a brief review of the submission strategy.

The follow-up emails, spaced at measured intervals, reference prior correspondence by date. They add new information: a recently published FDA final guidance, a warning letter issued to a competitor, a revised timeline for a relevant FDA pilot program. The sequence demonstrates ongoing attention to the regulatory environment the recipient inhabits.

ROI Wire composes each email. Your firm reviews for technical accuracy. The correspondence is sent from infrastructure ROI Wire operates, with your firm's name and reply path. The recipient responds to your consultants directly.

Direct Mail: The Document That Sits on the Desk

A physical letter carries weight in regulatory affairs. These are individuals who still review paper submissions, who handle FDA correspondence in formal document form, who understand that a mailed letter represents deliberate effort.

The Direct Mail piece is a single page, often referencing a specific public FDA action: a warning letter to a company in the same therapeutic area, a revised guidance with a compliance date, a new draft rule open for comment. The letter names the recipient's company and the specific regulatory status or milestone that makes the timing relevant.

A quality director at a facility with recent data integrity observations receives a letter citing 21 CFR 211 and the FDA's current emphasis on ALCOA+ principles in laboratory settings. It notes the trend in recent warning letters toward repeat observations. It proposes a preliminary assessment of the laboratory data governance program.

The letter includes no pricing. No contract. A single sentence offers a conversation. The phone follow-up, made ten to fourteen days after mailing, references the letter by date and subject. The recipient has seen it. They know why you are calling.

The Phone Follows the Letters

The call is not an introduction. It is a continuation. The script opens with the date of the mailed letter and the regulatory event it named. The recipient is already oriented.

"Ms. Chen, ROI Wire sent a letter on March 3 regarding the 483 observation your firm received in February on batch record review procedures. Your compliance consultant is available to discuss the response timeline and the FDA's current expectations for similar manufacturers."

The call accepts a decline gracefully. It accepts a request for more information. It accepts a meeting. It does not push past a clear no. The value is in the precision of the opening, not the persistence of the close.

What the Correspondence Says and What It Does Not

The letters and emails name real regulatory events. They do not name client engagements, even anonymized ones, unless your firm has explicitly approved the reference. They do not claim "FDA relationships" or "former FDA insiders" unless that is literally and verifiably true. They do not predict outcomes.

They do demonstrate that your firm tracks the regulatory environment the recipient operates in. That tracking, sustained over a sequence of correspondence, builds credibility before a conversation occurs.

The tone is that of a competent peer, not a vendor. The writer knows what a Q-Sub meeting is for. Knows the difference between a 510(k) and a PMA. Knows that a biologics license application has its own inspection pathway. This is not simulated expertise. ROI Wire researches each vertical thoroughly and your firm reviews every sequence before it sends.

Revenue Share and Retainer Structures

Some FDA compliance consulting engagements suit a revenue share arrangement. The client firm covers the cost of list building, correspondence composition, and sending infrastructure. ROI Wire receives a share of the revenue from engagements that originate through this pipeline. This aligns the work with actual client relationships won, not with activity metrics.

Other engagements run on a fixed retainer, appropriate where the compliance work itself is project-based with defined scoping, or where the firm prefers predictable marketing expenditure. The structure is discussed and set before any correspondence sends. There is no standard package.

What does not work: any arrangement where the consultant is unwilling to invest in sustained outreach, or where the firm expects immediate meetings from a single email. FDA compliance decisions involve multiple stakeholders and regulatory timelines measured in quarters. The correspondence builds presence over that horizon.

Data Handling and Regulatory Sensitivity

ROI Wire does not access your client files, FDA submissions, or proprietary regulatory strategies. The correspondence is composed from public and commercially available information: FDA databases, SEC disclosures, patent filings, published warning letters and 483 observations. Your firm reviews all technical content before it sends.

Where a prospect responds with confidential information, that correspondence routes directly to your firm. ROI Wire does not hold, review, or process protected regulatory documents. This separation is maintained throughout the engagement.

Who This Works For

The model fits firms with specific, demonstrable expertise: a track record with 510(k) submissions in cardiovascular devices, with remediation of data integrity observations for sterile manufacturers, with IND-enabling studies for oncology biologics. The narrower the specialization, the more precise the correspondence, the stronger the response.

It fits firms with the capacity to engage new clients within a reasonable window. A quality director responding to a letter about an impending FDA inspection needs a response within days, not weeks.

It fits firms willing to invest in a pipeline that builds over months. The first email may not produce a meeting. The fifth, timed to a new FDA guidance or a competitor's warning letter, often does.

Who This Does Not Work For

Firms that treat compliance consulting as a generalist service, interchangeable with any other quality consultant, will find the specificity of this correspondence exposes their thinness. The letters name CFR sections and guidance documents. A firm that cannot speak fluently to those specifics should not send them.

Firms that are price-competitive and volume-oriented are poorly suited. The buyers reached through this channel are managing regulatory risk, not shopping for the lowest hourly rate. They respond to demonstrated expertise, not to cost positioning.

Firms unwilling to let ROI Wire research and name their actual specialization, preferring vague positioning as "regulatory experts," defeat the mechanism. The correspondence works because it is specific. Vagueness is invisible.

The Work of Sustained Outreach

A single letter or email is easily ignored. A sequence, each adding relevant information, each timed to the regulatory calendar, becomes harder to dismiss. The recipient begins to recognize the sender's name. Begins to associate it with timely, useful information about their regulatory environment. When the 483 arrives, when the pre-submission meeting is scheduled, when the warning letter is published, the name is already present.

This is not a campaign. It is correspondence, maintained over time, to individuals whose regulatory obligations make them genuine prospects for your firm's specific expertise. The work is precise, repetitive, and effective in a vertical where buying decisions are deliberate and expertise is the only currency.

ROI Wire composes the letters, operates the sending infrastructure, manages the follow-up sequence, and trains the phone follow-up. Your firm provides the expertise that makes the content credible and handles the conversations that result. The division is clean. The pipeline is yours.